Current impact and application of abuse-deterrent opioid formulations in clinical practice

Ya Han Lee, Daniel L. Brown, Hsiang Yin Chen

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Background: Abuse-deterrent formulations (ADFs) represent one novel strategy for curbing the potential of opioid abuse. Objective: We aim to compare and contrast the characteristics and applications of current abusedeterrent opioid products in clinical practice. Methods: Literature searches were conducted in databases (Pubmed Medline, International Pharmaceutical Abstracts, Google Scholar) and official reports. Relevant data were screened and organized into: 1) epidemiology of opioid abuse, 2) mitigation strategies for reducing opioid abuse, 3) development of ADFs, and 4) clinical experience with these formulations. Results: Increasing trends of opioid abuse and misuse have been reported globally. There are 5 types of abuse-deterrent opioid products: physical chemical barrier, combined agonist/antagonist, sequestered aversive agent, prodrug, and novel delivery system. The advantages and disadvantages of the 5 options are discussed in this review. A total of 9 products with abuse-deterrent labels have been approved by the Food and Drug Administration (FDA). The rates of abuse, diversion, and overdose deaths of these new products are also discussed. A framework for collecting in-time data on the efficacy, benefit and risk ratio, and cost-effectiveness of these new products is suggested to facilitate their optimal use. Limitations: The present review did not utilize systematic review standards or meta-analytic techniques, given the large heterogeneity of data and outcomes reviewed. Conclusions: ADFs provide an option for inhibiting the abuse or misuse of oral opioid products by hindering extraction of the active ingredient, preventing alternative routes of administration, or causing aversion. Their relatively high costs, uncertain insurance policies, and limited data on pharmacoeconomics warrant collaborative monitoring and assessment by government agencies, pharmaceutical manufacturers, and data analysis services to define their therapeutic role in the future.

Original languageEnglish
Pages (from-to)E1003-E1023
JournalPain Physician
Volume20
Issue number7
Publication statusPublished - Nov 1 2017

Fingerprint

Opioid Analgesics
Sequestering Agents
Government Agencies
Pharmaceutical Economics
Architectural Accessibility
Prodrugs
United States Food and Drug Administration
Insurance
PubMed
Pharmaceutical Preparations
Cost-Benefit Analysis
Epidemiology
Odds Ratio
Databases
Costs and Cost Analysis

Keywords

  • Abuse liking
  • Abuse-deterrent formulations
  • ADF
  • Clinical application
  • Cost impact
  • FDA guidance
  • Generic abuse-deterrent formulation
  • Opioid abuse
  • Physician attitude
  • Post-marketing

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Current impact and application of abuse-deterrent opioid formulations in clinical practice. / Lee, Ya Han; Brown, Daniel L.; Chen, Hsiang Yin.

In: Pain Physician, Vol. 20, No. 7, 01.11.2017, p. E1003-E1023.

Research output: Contribution to journalReview article

@article{2f7838b03959416b8c024bcd2e50c9ee,
title = "Current impact and application of abuse-deterrent opioid formulations in clinical practice",
abstract = "Background: Abuse-deterrent formulations (ADFs) represent one novel strategy for curbing the potential of opioid abuse. Objective: We aim to compare and contrast the characteristics and applications of current abusedeterrent opioid products in clinical practice. Methods: Literature searches were conducted in databases (Pubmed Medline, International Pharmaceutical Abstracts, Google Scholar) and official reports. Relevant data were screened and organized into: 1) epidemiology of opioid abuse, 2) mitigation strategies for reducing opioid abuse, 3) development of ADFs, and 4) clinical experience with these formulations. Results: Increasing trends of opioid abuse and misuse have been reported globally. There are 5 types of abuse-deterrent opioid products: physical chemical barrier, combined agonist/antagonist, sequestered aversive agent, prodrug, and novel delivery system. The advantages and disadvantages of the 5 options are discussed in this review. A total of 9 products with abuse-deterrent labels have been approved by the Food and Drug Administration (FDA). The rates of abuse, diversion, and overdose deaths of these new products are also discussed. A framework for collecting in-time data on the efficacy, benefit and risk ratio, and cost-effectiveness of these new products is suggested to facilitate their optimal use. Limitations: The present review did not utilize systematic review standards or meta-analytic techniques, given the large heterogeneity of data and outcomes reviewed. Conclusions: ADFs provide an option for inhibiting the abuse or misuse of oral opioid products by hindering extraction of the active ingredient, preventing alternative routes of administration, or causing aversion. Their relatively high costs, uncertain insurance policies, and limited data on pharmacoeconomics warrant collaborative monitoring and assessment by government agencies, pharmaceutical manufacturers, and data analysis services to define their therapeutic role in the future.",
keywords = "Abuse liking, Abuse-deterrent formulations, ADF, Clinical application, Cost impact, FDA guidance, Generic abuse-deterrent formulation, Opioid abuse, Physician attitude, Post-marketing",
author = "Lee, {Ya Han} and Brown, {Daniel L.} and Chen, {Hsiang Yin}",
year = "2017",
month = "11",
day = "1",
language = "English",
volume = "20",
pages = "E1003--E1023",
journal = "Pain Physician",
issn = "1533-3159",
publisher = "Association of Pain Management Anesthesiologists",
number = "7",

}

TY - JOUR

T1 - Current impact and application of abuse-deterrent opioid formulations in clinical practice

AU - Lee, Ya Han

AU - Brown, Daniel L.

AU - Chen, Hsiang Yin

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Background: Abuse-deterrent formulations (ADFs) represent one novel strategy for curbing the potential of opioid abuse. Objective: We aim to compare and contrast the characteristics and applications of current abusedeterrent opioid products in clinical practice. Methods: Literature searches were conducted in databases (Pubmed Medline, International Pharmaceutical Abstracts, Google Scholar) and official reports. Relevant data were screened and organized into: 1) epidemiology of opioid abuse, 2) mitigation strategies for reducing opioid abuse, 3) development of ADFs, and 4) clinical experience with these formulations. Results: Increasing trends of opioid abuse and misuse have been reported globally. There are 5 types of abuse-deterrent opioid products: physical chemical barrier, combined agonist/antagonist, sequestered aversive agent, prodrug, and novel delivery system. The advantages and disadvantages of the 5 options are discussed in this review. A total of 9 products with abuse-deterrent labels have been approved by the Food and Drug Administration (FDA). The rates of abuse, diversion, and overdose deaths of these new products are also discussed. A framework for collecting in-time data on the efficacy, benefit and risk ratio, and cost-effectiveness of these new products is suggested to facilitate their optimal use. Limitations: The present review did not utilize systematic review standards or meta-analytic techniques, given the large heterogeneity of data and outcomes reviewed. Conclusions: ADFs provide an option for inhibiting the abuse or misuse of oral opioid products by hindering extraction of the active ingredient, preventing alternative routes of administration, or causing aversion. Their relatively high costs, uncertain insurance policies, and limited data on pharmacoeconomics warrant collaborative monitoring and assessment by government agencies, pharmaceutical manufacturers, and data analysis services to define their therapeutic role in the future.

AB - Background: Abuse-deterrent formulations (ADFs) represent one novel strategy for curbing the potential of opioid abuse. Objective: We aim to compare and contrast the characteristics and applications of current abusedeterrent opioid products in clinical practice. Methods: Literature searches were conducted in databases (Pubmed Medline, International Pharmaceutical Abstracts, Google Scholar) and official reports. Relevant data were screened and organized into: 1) epidemiology of opioid abuse, 2) mitigation strategies for reducing opioid abuse, 3) development of ADFs, and 4) clinical experience with these formulations. Results: Increasing trends of opioid abuse and misuse have been reported globally. There are 5 types of abuse-deterrent opioid products: physical chemical barrier, combined agonist/antagonist, sequestered aversive agent, prodrug, and novel delivery system. The advantages and disadvantages of the 5 options are discussed in this review. A total of 9 products with abuse-deterrent labels have been approved by the Food and Drug Administration (FDA). The rates of abuse, diversion, and overdose deaths of these new products are also discussed. A framework for collecting in-time data on the efficacy, benefit and risk ratio, and cost-effectiveness of these new products is suggested to facilitate their optimal use. Limitations: The present review did not utilize systematic review standards or meta-analytic techniques, given the large heterogeneity of data and outcomes reviewed. Conclusions: ADFs provide an option for inhibiting the abuse or misuse of oral opioid products by hindering extraction of the active ingredient, preventing alternative routes of administration, or causing aversion. Their relatively high costs, uncertain insurance policies, and limited data on pharmacoeconomics warrant collaborative monitoring and assessment by government agencies, pharmaceutical manufacturers, and data analysis services to define their therapeutic role in the future.

KW - Abuse liking

KW - Abuse-deterrent formulations

KW - ADF

KW - Clinical application

KW - Cost impact

KW - FDA guidance

KW - Generic abuse-deterrent formulation

KW - Opioid abuse

KW - Physician attitude

KW - Post-marketing

UR - http://www.scopus.com/inward/record.url?scp=85035020735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035020735&partnerID=8YFLogxK

M3 - Review article

C2 - 29149148

AN - SCOPUS:85035020735

VL - 20

SP - E1003-E1023

JO - Pain Physician

JF - Pain Physician

SN - 1533-3159

IS - 7

ER -